Johnson & Johnson Neuropsychiatry Pipeline Advances with New APA/ASCP Data
Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.
Johnson & Johnson reinforces its leadership in neuropsychiatry, presenting pivotal data for seltorexant and aticaprant at the 2024 APA and ASCP meetings.
Novo Nordisk announced today that its blockbuster drug semaglutide failed to slow the progression of early-stage Alzheimer’s disease in two large-scale Phase 3 clinical trials, [Read More…]
Dr. James D. Watson, the Nobel laureate who fundamentally changed biology by co-discovering the DNA double helix, has died at 97. While his 1953 breakthrough ushered in the age of modern genetics
Eli Lilly and Company announced the European Commission has granted marketing authorization for Kisunla (donanemab) to treat early symptomatic Alzheimer’s disease. The therapy demonstrated a significant slowing of cognitive and functional decline and is unique for supporting a finite treatment course.
Eli Lilly and Company announced results from the long-term extension of the Phase 3 TRAILBLAZER-ALZ 2 study, demonstrating that participants treated with Kisunla (donanemab-azbt) for early symptomatic Alzheimer’s disease showed a continued slowing of decline over three years.
One of the most intriguing and intricate organelles in eukaryotic cells is the endoplasmic reticulum (ER), which is essential for calcium homeostasis, lipid metabolism, and [Read More…]
The University of California San Francisco Medical Center researchers have discovered four different gene classes that contribute to the explanation of why certain brain regions [Read More…]
A significant step in Alzheimer’s care: The FDA’s updated approval for the Amyvid PET scan allows for better diagnosis and patient selection for the latest amyloid-based treatments
Swiss healthcare giant Roche is advancing prasinezumab, a potential first-in-class anti-alpha-synuclein antibody for early Parkinson’s disease, into Phase III trials. This decision follows encouraging data from the Phase IIb PADOVA study and its long-term follow-up, suggesting the drug offers clinical benefits.
Amino acids are the basic structural units of proteins, which are critical macromolecules of all living organisms. Proteins play a role in almost every aspect [Read More…]